Arvinas, Inc. (ARVN) News
Follow Arvinas, Inc. (ARVN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Arvinas Reports Third-Quarter Revenue of $500K, Net Loss of $53.9M
Revenue fell from $41.9M a year earlier, while net loss widened from $35.1M and diluted loss per share increased from $0.48 to $0.82.
EQUITY | Nov 03, 2026, 09:12 PM UTC
M
Arvinas Q3 Net Loss Widens 54% to $53.9 Million as Revenue Falls 99%
Arvinas reported a third-quarter net loss of $53.9 million, up 54%, while revenue fell 99% to $500,000.
EQUITY | Nov 03, 2026, 12:11 PM UTC
M
Arvinas Reports Third-Quarter 2026 Results and Starts ARV-6723 Trial Dosing
Arvinas says it initiated dosing in a Phase 1/2 trial of ARV-6723, an oral immuno-oncology PROTAC. The supplied body is truncated and provides no financial figures.
EQUITY | Nov 03, 2026, 12:02 PM UTC
M
Arvinas to Review Third-Quarter 2026 Results
EQUITY | Oct 27, 2026, 11:14 AM UTC
L
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. NASDAQ:ARVN (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, tod
EQUITY | Sep 29, 2026, 08:08 PM UTC
L
Arvinas, Inc. (ARVN) Doses First Patient in ARV-6723 Phase 1/2 Trial
Arvinas dosed the first patient in a Phase 1/2 trial of ARV-6723, an oral HPK1-targeting PROTAC, as monotherapy and with pembrolizumab in advanced solid tumors.Material DetailsContext by AI AnalystThis is an early-stage
NEWS | Sep 28, 2026, 11:08 AM UTC
L
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors —NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. NASDAQ:ARVN, a
REGULATION | Sep 28, 2026, 11:08 AM UTC
H
Arvinas Q2 2026 Earnings Call Transcript
Arvinas (NASDAQ: ARVN ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcr
LIVE | Sep 25, 2026, 11:25 AM UTC
L
ARVN outlines clinical pipeline readouts across four programs
ARVN said key data readouts are expected for four programs over the next 15 months. It highlighted ARV-393 and ARV-102 nearing pivotal milestones, plus biomarker-driven progress for SBMA and HPK1.
EQUITY | Sep 08, 2026, 07:22 PM UTC
L
ARVN pipeline update: four programs advance; data due within 15 months
ARVN said four programs are advancing as it shifts to a robust clinical pipeline. ARV-393 and ARV-102 are progressing in hematology and neurodegeneration, while SBMA and HPK1 target rare disease and immuno-oncology; key
EQUITY | Sep 08, 2026, 06:43 PM UTC
L
Arvinas management to take part in upcoming investor fireside chats
Arvinas, Inc. said management will participate in fireside chats at upcoming investor conferences.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
ARVN - Arvinas to Participate in Upcoming Investor Conferences
ARVN - Arvinas to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 08:01 PM UTC
L
Arvinas grants 45,696 RSUs under Nasdaq Rule 5635(c)(4)
Arvinas announced it granted 45,696 restricted stock units under Nasdaq Listing Rule 5635(c)(4), an inducement equity award.
EQUITY | Sep 01, 2026, 08:08 PM UTC
L
ARVN announces Nasdaq Rule 5635(c)(4) inducement grant
Arvinas announced an inducement grant under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:01 PM UTC
L
ARVN - Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ARVN - Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 04, 2026, 11:01 AM UTC